Phase II trial of vindesine in the treatment of lymphomas, breast cancer, and other solid tumors

T. P. Miller, S. E. Jones, A. Chester

Research output: Contribution to journalArticle

8 Scopus citations


A phase II study of vindesine in 41 evaluable patients demonstrated the drug to be active in heavily pretreated patients ith breast cancer, non-Hodgkin's lymphoma, and other tumors. There were two partial responses in 11 patients with breast ancer (18%) and five partial responses and one complete response in 11 patients with non-Hodgkin's lymphoma (40%). Other esponses were seen in small cell carcinoma of the lung, ovarian carcinoma, and Hodgkin's disease. Prior vinca exposure did nt adversely affect the response rate. Neutropenia was dose-limiting. Neurotoxic effects occurred in 10% of the patients. high incidence of local tissue reactions at the injection site (27%) could be reduced by a careful administration technique Vindesine should be studied further in combination with other agents.

Original languageEnglish (US)
Pages (from-to)1001-1003
Number of pages3
JournalCancer Treatment Reports
Issue number8-9
StatePublished - Dec 1 1980


ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this